Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (DE NOVO) | Bardet-Biedl Syndrome (BBS) | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (SWITCH) | Obesity due to biallelic POMC, PCSK1, LEPR deficiency or BBS | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Rhythm Pharmaceuticals Inc. | Setmelanotide | Prader-Willi Syndrome | Phase 2 | Data Released | Subcutaneous | Genetic Disorder |
| Rhythm Pharmaceuticals Inc. | Bivamelagon - (SIGNAL) | Acquired hypothalamic obesity | Phase 2 | Data Released | Oral | Endocrinology |
| Rhythm Pharmaceuticals Inc. | Bivamelagon (LB54640) | Healthy overweight adults | Phase 2 | Data Released | Oral | N/A |
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (DAYBREAK) | Variants in one of 31 additional genes with MC4R pathway relevance | Phase 2 | Ongoing | Subcutaneous | Genetic Disorder |
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (Basket) | POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders | Phase 2 | Trial Completed | Subcutaneous | Genetic Disorder |
| Rigel Pharmaceuticals Inc. | Fostamatinib (NIH ACTIV-4) | COVID-19 | Phase 2/3 | Data Released | Oral | COVID-19 |
